All conditions

Gout

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

362
Trials on record
37
Recruiting now
1
Australian sites
7
Phase 3 trials
1
PBS medicines
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Gout →

Get alerts when Gout trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Gout

Gout is a type of arthritis caused by a build-up of uric acid in the blood. When uric acid levels get too high, it can form sharp, needle-like crystals that collect in and around joints. This most often affects the big toe, but it can also occur in the ankles, knees, wrists, and fingers. These crystal deposits can cause sudden episodes of intense pain, swelling, redness, and warmth in the affected joint. These episodes are often called gout attacks or flares, and they can come on very quickly, sometimes overnight.

Gout is one of the most common forms of inflammatory arthritis in Australia, affecting roughly 70,000 Australians. It is more common in men, particularly those over 40, though women can also develop it, often after menopause. Certain groups, including Aboriginal and Torres Strait Islander peoples, are affected at higher rates. Factors such as diet, alcohol consumption, some medications, kidney function, and family history can all play a role in a person's uric acid levels and their likelihood of developing gout.

Treatment for gout is generally focused on two things: managing the pain and inflammation during a flare, and reducing uric acid levels over the longer term to help prevent future attacks. Doctors may recommend lifestyle changes alongside medication, and regular monitoring of uric acid levels through blood tests is a common part of ongoing care. Speaking openly with your GP or specialist about your symptoms and any concerns is a good starting point for understanding what options might be right for your situation.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Gout in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

PBS-subsidised medicines for Gout

1 medicine listed on the PBS for Gout. Filter by authority type, or open the full table below.

What the authority types mean Unrestricted: no clinical criteria; a doctor can prescribe it on the PBS for any appropriate use. Restricted benefit: subsidised only for the specific conditions or uses set out by the PBS. Streamlined authority: restricted, but the doctor does not need prior approval; they record a streamlined authority code confirming you meet the criteria. Authority required: restricted, and the doctor must get prior approval from Services Australia (by phone or online) before it is subsidised. Source: Pharmaceutical Benefits Scheme (pbs.gov.au).
Full PBS medicines table 1 listed

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. Prices shown are the PBS-determined dispensed price. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest.

Medicine Brand(s) Listed for
Febuxostat Adenuric gout Chronic AU$35.21 Streamlined authority

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Research pipeline

Where trials for Gout currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Gout.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Gout by country. Australia is highlighted.

Showing the top 10 of 34 countries with trial sites.

Clinical trials for Gout

Showing 45 of 45 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT01029652 · Novartis Pharmaceuticals Phase 3 · 17 countries Completed
Completed Phase 3 Est. completion 1 October 2010
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇨🇴 CO🇪🇪 EE🇩🇪 DE Guatemala🇱🇻 LV +9 more

**Who might be able to join this trial:** - You have been diagnosed with acute gout according to a standard set of medical classification rules (confirm with trial site) - Your current gout flare started within the last 5 days before joining the study - Your pain level is at least 50 out of 100 on a pain rating scale a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01391325 · Ardea Biosciences, Inc. Phase 4 · 7 countries Completed
Completed Phase 4 Est. completion 1 January 2013
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇩🇪 DE🇳🇿 NZ🇿🇦 ZA🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with gout according to a specific set of recognised medical guidelines. - If you are not currently taking medication to lower uric acid, your uric acid blood level must be 8.0 mg/dL or higher at the screening appointment. - If you are currently taking...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
🇦🇺 NCT01470989 · Novartis Pharmaceuticals Phase 3 · 9 countries Completed
Completed Phase 3 Est. completion 1 May 2013
🇦🇺 AU🇨🇦 CA🇪🇪 EE🇩🇪 DE🇱🇻 LV🇱🇹 LT🇷🇺 RU🇺🇦 UA +1 more

Who might be able to join this trial: - You must have already completed one of two specific earlier stages of this study (known as CACZ885H2356E2 or CACZ885H2357E2) (confirm with trial site) - You must have previously received treatment with the study drug, canakinumab, during the earlier parts of this research program...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01493531 · Ardea Biosciences, Inc. Phase 3 · 11 countries Completed
Completed Phase 3 Est. completion 1 May 2014
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇩🇪 DE🇳🇿 NZ🇵🇱 PL🇿🇦 ZA🇪🇸 ES +3 more

**Who might be able to join this trial:** - You are able to understand what the study involves, are aware of the risks, and are willing to sign a consent form before anything begins. - You have been diagnosed with gout according to standard medical guidelines. - You have been taking allopurinol (and only allopurinol) a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01508702 · Ardea Biosciences, Inc. Phase 3 · 7 countries Completed
Completed Phase 3 Est. completion 1 October 2013
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇩🇪 DE🇳🇿 NZ🇿🇦 ZA🇺🇸 US

**Who might be able to join this trial:** - You are able to understand what the study involves, accept the risks, and are willing to sign a consent form before anything begins. - You have been diagnosed with gout according to a recognised set of medical classification guidelines. - Your uric acid level in your blood wa...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01510769 · Ardea Biosciences, Inc. Phase 3 · 6 countries Completed
Completed Phase 3 Est. completion 1 June 2014
🇦🇺 AU🇨🇦 CA🇳🇿 NZ🇵🇱 PL🇨🇭 CH🇺🇸 US

**Who might be able to join this trial:** - You are able to understand what the study involves, accept the risks, and are willing to sign a consent form before anything begins. - You are willing to attend all required visits and follow the study schedule. - You have been diagnosed with gout according to standard medic...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01650246 · Ardea Biosciences, Inc. Phase 3 · 7 countries Completed
Completed Phase 3 Est. completion 1 April 2014
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇩🇪 DE🇳🇿 NZ🇿🇦 ZA🇺🇸 US

Who might be able to join this trial: - You are able to understand what the study involves and the possible risks, and you are willing to sign a consent form before any study activities begin. - You took part in and completed a previous related study (called RDEA594-303) and were still actively taking the study medicat...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01808144 · Ardea Biosciences, Inc. Phase 3 · 6 countries Completed
Completed Phase 3 Est. completion 9 August 2016
🇦🇺 AU🇨🇦 CA🇳🇿 NZ🇵🇱 PL🇨🇭 CH🇺🇸 US

Who might be able to join this trial: - You must be able to understand what the study involves and the risks, and be willing to sign a consent form before anything begins. - You must have completed the full 12-month treatment period in a previous related study (Study RDEA594-304) and have been actively taking and toler...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07145229 · Atom Therapeutics Co., Ltd Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 1 May 2026
🇦🇺 AU🇨🇳 CN🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 70 years old (inclusive), either male or female - Your body weight falls within a healthy-to-obese range (BMI between 18 and 40) - You have been diagnosed with gout (a type of arthritis caused by uric acid crystals in the joints) - You have had 2 or mo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03524222 · Brigham and Women's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2030
🇺🇸 US

**Who might be able to join this trial:** - You live within 5 miles or 20 minutes' drive from the emergency department - You are 18 years old or older - You are able to give your own consent, or you have someone who can consent on your behalf while you agree to take part - You can identify a caregiver who is willing t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04695028 · Lille Catholic University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2023
🇫🇷 FR

**Who might be able to join this trial:** - You have been diagnosed with gout (based on 2015 medical guidelines), OR a condition called calcium pyrophosphate crystal disease (CPPD), OR a condition called hydroxyapatite crystal rheumatism (HCR), where calcium deposits are visible on medical scans - You are someone who h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04875702 · Massachusetts General Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 September 2028
🇺🇸 US

**Who might be able to join this trial:** - You are willing and able to sign a consent form agreeing to take part in the study. - You are between 18 and 90 years old. - You are a patient at one of the participating primary care clinics and have had at least one visit there in the past 3 years. - You have been diagnose...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05109936 · University Hospital, Rouen Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2027
🇫🇷 FR

**Who might be able to join this trial:** - You are having a gout attack that started no more than 5 days ago, diagnosed using standard medical criteria - The gout attack is affecting one or more joints in your arms or legs (such as your foot, knee, or wrist) - This is either your first gout attack, or a new attack wh...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05507723 · University of Edinburgh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2028
🇬🇧 GB

Who might be able to join this trial: - You are willing and able to give your consent to take part in the trial. - You are 18 years old or older. - You have had at least one gout flare-up (attack) in the past 12 months. - You have been formally diagnosed with gout based on recognised medical guidelines. - Your blood ur...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05546593 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇫🇷 FR

Who might be able to join this trial: - You are an adult (18 years or older) - You have been diagnosed with gout according to specific medical guidelines (the 2015 ACR/EULAR criteria — confirm with trial site if unsure which criteria your diagnosis was based on) - You are able to understand and agree to the terms of ta...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05658575 · Olatec Therapeutics, Inc. Phase 3 · 5 countries Recruiting
Recruiting Phase 3 Est. completion 31 December 2026
🇫🇷 FR🇮🇱 IL🇳🇱 NL🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older (male or female) - You have been diagnosed with gout, confirmed either by a lab test of fluid from the affected joint, by imaging that shows urate (crystal) deposits in the joint, or by a documented history of gout in that joint or at least 2...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06092346 · National Human Genome Research Institute (NHGRI) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2099
🇺🇸 US

**Who might be able to join this trial:** **If you have a known disorder of purine and pyrimidine metabolism (DPPM):** - You must be at least one month old - You have a medical history and test results that suggest you have a disorder affecting how your body processes certain chemical building blocks called purines an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06298071 · Shanghai Institute Of Biological Products Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing and able to give informed consent to participate. - Men and women between 18 and 70 years old. - Men who weigh at least 50 kg and women who weigh at least 45 kg, with a body mass index (BMI) between 19 and 30. - People with a confirmed gout diagnosis (...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06534554 · University of Alabama at Birmingham Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇺🇸 US

Who might be able to join this trial: - You are 18 years old or older - You are able to communicate and understand English or Spanish - You have been confirmed to have an acute gout flare (a sudden, painful gout attack) during a visit to the emergency department, based on a review of your medical records Who may not b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06622603 · Seoul National University Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 19 February 2027
🇰🇷 KR

**Who might be able to join this trial:** - You are aged 19 or older but under 80 years old and have been diagnosed with gout - You have been taking gout medication to lower uric acid levels (either allopurinol, febuxostat, or both together) for at least the past 5 years - You have had at least 5 blood tests measuring...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06629376 · Shenyang Sunshine Pharmaceutical Co., LTD. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 20 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with gout (based on 2015 international gout classification guidelines) and are not currently having a gout flare-up. - Your blood uric acid level is higher than 420 µmol/L (7 mg/dl) at the screening visit. - Your blood uric acid level has previously be...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06669000 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 24 September 2032
🇫🇷 FR

Who might be able to join this trial: - You must be 18 years of age or older - You have been diagnosed with gout based on recognised international medical guidelines (the 2015 ACR/EULAR criteria) - Your uric acid level in the blood is higher than 60 mg/L (confirm with trial site if you are unsure of your levels) - An u...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06674109 · Massachusetts General Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 28 February 2028
🇺🇸 US

**Who might be able to join this trial:** - You are willing and able to sign a consent form agreeing to take part in the study - You have been diagnosed with gout according to standard medical guidelines (confirm with trial site) - You have had at least one gout flare (painful gout attack) in the past 12 months - Your...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06694012 · Osaka Metropolitan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2050
🇯🇵 JP

Who might be able to join this trial: - The inclusion criteria were not specified in the available information (confirm with trial site) Who may not be able to join: - Women who may be pregnant are not able to take part in this trial Important: Always verify eligibility with the trial site directly before applying.

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06834230 · Saga University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 July 2027
🇯🇵 JP

**Who might be able to join this trial:** - You are 20 years of age or older (any gender) - You have high uric acid levels in your blood (above 7.0 mg/dL), and either have not taken any uric acid-lowering medication in the past 27 days, or stopped taking such medication more than 27 days ago - You have high blood pres...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06863701 · Laboratorios Silanes S.A. de C.V. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2026
🇲🇽 MX

**Who might be able to join this trial:** - You are willing to take part and sign a consent form agreeing to participate. - If you are a woman who could become pregnant and is sexually active, you must be willing to use an accepted form of contraception (such as condoms or hormonal methods) during the study. - You have...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06924658 · Mostafa Bahaa Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 20 November 2026
🇪🇬 EG

Who might be able to join this trial: - You have been diagnosed with gouty arthritis (a type of gout that causes painful joint inflammation) by a doctor, using standard international diagnostic guidelines. Who may not be able to join: - You have a serious condition affecting your whole body, such as heart disease, neu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06966635 · Huashan Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with gout according to recognized international medical guidelines (ACR/EULAR 2015 criteria) - You are between 18 and 70 years old (any gender) - Your most recent gout attack happened at least 2 weeks ago - You have been taking a stable dose of uric a...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06971146 · University of Aarhus Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇩🇰 DK

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with gout according to a recognised set of medical classification guidelines (confirm with trial site) - Your kidneys are working at a sufficient level, as measured by a standard kidney function test (confirm with trial...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06995339 · Mostafa Bahaa Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 20 August 2026
🇪🇬 EG

**Who might be able to join this trial:** - You are under 18 years old (a child or teenager) - You have been diagnosed with gout and your uric acid blood level is below 7 mg/dl - You have been diagnosed with obesity, meaning your Body Mass Index (BMI) is 30 or higher **Who may not be able to join:** - You have any typ...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07002762 · OMNIFARMA LLC Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2025
🇺🇦 UA

**Who might be able to join this trial:** - Your blood test shows a uric acid level between 360–540 μmol/L (for women) or 420–540 μmol/L (for men) - You are between 35 and 65 years old at the start of the trial - A specialist has examined you and found no signs of gout or other health problems caused by high uric acid...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07089875 · Crystalys Therapeutics Phase 3 · 3 countries Recruiting
Recruiting Phase 3 Est. completion 29 November 2027
🇵🇱 PL🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 75 years old at the time of signing the consent form. - You have been formally diagnosed with gout for at least 1 year, based on recognised medical guidelines. - You have had at least 2 gout flare-ups in the past 12 months, either reported by you or rec...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07089888 · Crystalys Therapeutics Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2027
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 75 years old (inclusive) at the time of signing the consent form. - You have been diagnosed with gout (based on a specific set of medical guidelines) for at least 1 year. - You have at least one tophus (a firm lump caused by uric acid buildup) on your h...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07141888 · Örebro University, Sweden Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇸🇪 SE

**Who might be able to join this trial:** - You have signed a consent form agreeing to take part before any study activities begin - You are between 18 and 80 years old - Your weight is within a moderate range relative to your height (BMI between 17.5 and 40) - Your blood uric acid level is higher than normal (above 40...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07280156 · Protalix Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇬🇪 GE🇮🇱 IL🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - Your weight is between 50 kg (about 110 lbs) and 150 kg (about 330 lbs) - You have gout and your uric acid levels have not been brought under control with standard medications, or you are unable to take those medications - You are willing to...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07343336 · Lille Catholic University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
French Polynesia

**Who might be able to join this trial:** - You are between 18 and 75 years old (inclusive) - You are willing and able to sign a consent form agreeing to take part - You are able to fast (go without eating or drinking) before giving biological samples - You are of Polynesian ancestry - You are covered by a social secu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07346079 · Massachusetts General Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 August 2027
🇺🇸 US

**Who might be able to join this trial:** - You are willing and able to sign a consent form agreeing to take part in the study - You are a man or woman between 18 and 85 years old - You have been diagnosed with gout according to recognised medical guidelines (confirm with trial site) - Your current gout flare (painful...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07362355 · Jiangsu HengRui Medicine Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have freely agreed to take part and are willing to follow all study procedures - Adults aged 18 to 75 years old (male or female) - People who have been taking febuxostat 40 mg per day at a steady dose for at least 6 weeks before joining, and whose blood uric acid...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07367971 · Atom Therapeutics Co., Ltd Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 July 2026
🇺🇸 US

Who might be able to join this trial: - You are between 18 and 75 years old and have been diagnosed with gout. - You have been taking Allopurinol once a day at a steady dose for at least 14 days before the study starts. - You have normal kidney function (this applies to one group in the study). - You have moderate kidn...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07388498 · Amgen Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 18 June 2028
Puerto Rico🇺🇸 US

**Who might be able to join this trial:** - You have agreed to take part and signed a consent form before any trial activities begin. - You are 18 years of age or older (or meet the legal adult age in your country, if that is older than 18). - You are willing and able to follow the treatment plan and attend all require...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07414394 · Innovent Biologics Technology Limited (Shanghai R&D Center) Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 April 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years old or older - Your body weight falls within a moderate range (BMI between 18 and 40) - You have been diagnosed with gout using recognised medical guidelines - Your blood uric acid level is above a certain threshold at the screening visit — the exact level de...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07490522 · Diakonhjemmet Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇳🇴 NO

Who might be able to join this trial: - You are 18 years old or older - You have been diagnosed with gout by a doctor - Your blood uric acid level is above a certain threshold (confirm with trial site for exact value) - A doctor has decided that you need medication to lower your uric acid levels - You own and can use a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07504146 · I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 October 2027
🇮🇹 IT

Who might be able to join this trial: - You have been diagnosed with a crystal joint disease called CPPD (calcium pyrophosphate deposition disease) using recognised medical classification standards, OR you have signs of CPPD visible on an ultrasound or X-ray even if you have no symptoms - You have been diagnosed with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07535034 · Crystalys Therapeutics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2027
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 75 years old (inclusive) at the time of signing the consent form. - You have been diagnosed with gout (based on specific medical guidelines) for at least 1 year, AND either you have had problems tolerating or been advised against taking allopurinol or...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07613138 · Beijing Zhecheng Biotechnology Co., Ltd. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 65 years old (any sex) - You have been diagnosed with high uric acid levels in your blood (called primary hyperuricemia), with levels in a specific range — either 420–540 μmol/L if you have no other health conditions, or 420–480 μmol/L if you also have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Gout. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

Arthritis Australia treats gout as one of the arthritis related conditions it covers.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.